Skye Bioscience Inc.(US:SKYE) Globenewswire·2026-01-09 22:34Core Viewpoint - Rosen Law Firm is reminding investors who purchased Skye Bioscience, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - The Class Period for the Skye Bioscience securities is from November 4, 2024, to October 3, 2025 [1]. - Investors who purchased Skye securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its success in this area [3]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Skye's defendants made materially false and misleading statements regarding the effectiveness of nimacimab, overstating its clinical, regulatory, and commercial prospects [4]. - The claims suggest that when the true details about nimacimab were revealed, investors suffered damages due to the misleading information provided by the defendants [4].